Bellevue Life Sciences Unit Agreement Filed

TL;DR

BLACU filed details on its unit structure: common stock, $11.50 warrants, and fractional share rights.

AI Summary

On January 9, 2025, Bellevue Life Sciences Acquisition Corp. (BLACU) entered into a material definitive agreement related to its units. The company's units consist of one share of common stock, one redeemable warrant exercisable for common stock at $11.50 per share, and one right to receive one-tenth of a share of common stock. This filing details the creation of financial obligations associated with these units.

Why It Matters

This filing clarifies the structure and terms of Bellevue Life Sciences Acquisition Corp.'s units, which is crucial for investors to understand their rights and potential future conversions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of unit structure and does not indicate new risks or significant changes in the company's financial health.

Key Numbers

• 1 — Share of Common Stock per Unit (Part of the unit structure)
• 1 — Redeemable Warrant per Unit (Part of the unit structure)
• 0.1 — Fraction of Share per Right per Unit (Part of the unit structure)

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Filer of the 8-K report
• January 9, 2025 (date) — Date of the earliest event reported
• 11.50 (dollar_amount) — Exercise price for redeemable warrants

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
• $1,200,000 — , 2024, in the principal amounts of (i) $1,200,000, (ii) $50,000, (iii) $140,000, and (iv)
• $50,000 — incipal amounts of (i) $1,200,000, (ii) $50,000, (iii) $140,000, and (iv) $300,000, res
• $140,000 — of (i) $1,200,000, (ii) $50,000, (iii) $140,000, and (iv) $300,000, respectively. On
• $300,000 — (ii) $50,000, (iii) $140,000, and (iv) $300,000, respectively. On January 9, 2025, th

Filing Documents

• d699740d8k.htm (8-K) — 33KB
• d699740dex101.htm (EX-10.1) — 9KB
• 0001193125-25-004439.txt ( ) — 223KB
• blacu-20250109.xsd (EX-101.SCH) — 5KB
• blacu-20250109_def.xml (EX-101.DEF) — 15KB
• blacu-20250109_lab.xml (EX-101.LAB) — 26KB
• blacu-20250109_pre.xml (EX-101.PRE) — 16KB
• d699740d8k_htm.xml (XML) — 9KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Amendment to Promissory Notes, dated January 9, 2025, between Bellevue Life Sciences Acquisition Corp. and Bellevue Global Life Sciences Investors, LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 10, 2025 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR